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ABSTRACT 
The past years have witnessed tremendous progress in the treatment of rheumatoid 
arthritis, a chronic debilitating autoimmune disease mainly characterized by joint 
inflammation with progressive tissue destruction and loss of function. This condition 
affects 0.5-1% of the population, is associated with important co-morbidities and 
represents a heavy economical burden. New strategies, employing early and aggressive 
therapies with classical drugs or new agents, have resulted in impressive improvements 
in controlling disease activity. In some cases they even lead to clinical remission. 
Despite potent and efficient biological agents that specifically modulate distinct 
pathological pathways a large proportion of patients remain unresponsive to these 
therapies; drug-free remission is also difficult to achieve since attempting 
discontinuation of treatment usually results in disease flare.  
In rheumatoid arthritis joints there is a constant activation of complex networks of 
cytokines and factors mediating immune interactions and inflammation, in which 
prostaglandin E2 (PGE2) and leukotriene B4 (LTB4) are important players and 
contributors to pathogenesis. Our research aimed to investigate the synovial expression 
of enzymes controlling prostaglandin E2 synthesis and degradation – cyclooxygenase 
(COX) 1 and 2, microsomal prostaglandin E2 synthase 1 (MPGES1) and 15-
prostaglandin dihydrogenase (15-PGDH) as well as enzymes involved in leukotriene 
synthesis, such as 5-lipoxygenase (LO) and 15-LO. In addition, we evaluated how 
traditional and new therapies influence these pathways, by analyzing enzyme 
expression before and after systemic treatment with tumor necrosis factor (TNF) 
antagonists, rituximab or methotrexate, as well as before and after intra-articular 
treatment with glucocorticoids. We also evaluated the in vitro effects of TNF 
antagonists and glucocorticoids on synovial fluid cells and that of methotrexate on 
synovial fibroblasts. 
We demonstrated that synovial tissue from RA patients displayed an important 
expression of enzymes involved in the metabolism of PGE2, as well as 5-LO and 15-
LO. MPGES1 and COX-2, the inflammation-inducible enzymes co-localized mainly in 
fibroblasts and macrophage-like cells and accounted for the local PGE2 production. 
Intra-articular glucocorticoids significantly reduced all enzymes involved in the PGE2 
cascade – COX-1 and COX-2, MPGES1 and 15-PGDH, but also 5-LO, responsible for 
leukotriene formation. However, they did not influence the expression of 15-LO, an 
enzyme involved in the formation of both pro-and anti-inflammatory lipid mediators. 
Regarding the effects of TNF blockers, rituximab or methotrexate, they did not alter the 
expression profile of enzymes involved in PGE2 metabolism despite showing clinical 
efficiency in improving disease activity. Although anti-TNF agents reduced the in vitro 
expression of MPGES1 and COX-2 in synovial fluid cells, the lack of effect ex vivo in 
biopsies emphasized once again the differences between synovial compartments and 
possibly the difficulty in mimicking the micro-environment at the site of inflammation 
in vitro. 
In conclusion, this thesis demonstrates that potent anti-rheumatic drugs currently 
used in the clinic with good efficiency also leave inflammatory pathways un-affected, 
which may account for subclinical ongoing disease activity. Blocking the PGE2 
pathway by using MPGES1 inhibitors as combination therapy may show benefit in 
dampening ongoing local inflammation.  
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FROM IMMUNITY TO INFLAMMATION AND BACK 
Innate and adaptive immunity 
Immunity is the host defense system that enables an organism to fight and eliminate 
foreign pathogens through coordinate reactions of cells and molecules. Its two main 
components are the innate and the adaptive immune systems. Innate immunity confers 
the initial protection and is a primordial defense complex that allows rapid recognition 
and annihilation of pathogens. Furthermore, through recognition of an appropriate 
stimulus, it provides the signals necessary required by the adaptive immune system to 
mount a proper response. It is an early barrier to pathogens that acts immediately but 
does not generate lasting protective immunity. By contrast, the hallmark of adaptive 
immunity is antigen specificity and immunological memory. It is a system that 
responds gradually and relies on the innate system for initial fight with invading 
pathogens and further recruits and activates T and B lymphocytes, the adaptive 
immunity effector cells
1
.  
Key components of the innate immunity are anatomical barriers, such as the 
epithelia in the skin, the gastro-intestinal and respiratory tracts, and professional 
phagocytes – neutrophils, macrophages and dendritic cells. Phagocytes can engulf 
microbes and destroy and eliminate them through a battery of degrading enzymes and 
free oxygen species. They achieve this by detecting pathogen- or damage- associated 
molecular patterns from invading microorganisms or injured structures. Dendritic cells 
are one bridge between innate and adaptive immunity via efficient antigen presentation. 
They capture the microbial antigen, migrate to peripheral lymphoid organs and display 
it via their major histocompatibilty complex (MHC) class II molecules, in conjunction 
with co-stimulatory signals, to T cells. This initiates the early events in adaptive 
immune responses, whereby antigen specific T and B cells are formed. There is also a 
dual interaction between T and B cells providing potential positive feedback loops: on 
the one hand B cells mature and differentiate into memory cells or antibody-secreting 
plasma cells through cell-surface interaction and delivery of cytokines from T cells; on 
the other hand T cells are activated through antigen presentation and signals provided 
by B cells.  
Upon encounter with the antigen, clonal expansion of antigen-specific T and B cells 
occurs. The specificity of T and B cells receptors is acquired by exposure to antigens 
through gene translocation and mutations that allow an increase in affinity and 
specificity. 
The molecular motifs shared by various classes of microbes are recognized by innate 
immune cells through genetically - encoded pattern recognition receptors, of which toll-
like receptors (TLRs) are a major family.  Engaging of these receptors results in 
activation of inflammatory pathway cascades and provides signals to alert immune 
cells, subsequently inducing the activation program of adaptive immunity. One of their 
established ligands is the lipopolyssacharide (LPS) component of the microbial wall, 
also called endotoxin. It specifically activates TLR4 and through activation of nuclear 
factor κB (NF-κB) induces the production of inflammatory mediators, cytokines and 
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bioactive lipids. Appropriate activation of the immune system and the inflammatory 
response are essential for defense against pathogens and for maintaining health. 
Inflammation and resolution 
Inflammation is a protective response of the organism’s immune system to injury or 
foreign challenge and is essential for restoration of tissue integrity and physiological 
homeostasis. It requires innate immunity and sometimes adaptive immune responses. 
The classical signs of inflammation – rubor, tumor, calor, dolor and functio laesa are 
the result of microcirculation events, activation of biological cascades and 
inflammatory cells and synthesis of a variety of cytokines, chemokines and lipid 
mediators, some with destructive potential. There are many mediators coordinating the 
initial events of acute inflammation, however many factors that drive inflammation also 
bring about its resolution
2
.  
In normal conditions the acute phase of inflammation is followed by an active 
resolution process under the strict control of endogenous mechanisms. The latter 
involves not only suppression of pro-inflammatory genes, but also activation of pro-
resolving mechanisms 
3
, with reversal of vascular changes, inhibition of leukocyte 
migration and activation, as well as clearance of inflammatory cells by apoptosis and 
phagocytosis. A balanced control of the inflammatory and resolution reactions is 
important in maintaining the body’s health state.  
Biologically active fatty acids derivatives have essential roles in propagating 
inflammatory reactions but also in the resolution phase. Prostaglandin E2 (PGE2) is a 
lipid derivative that regulates a variety of cellular events in T and B lymphocytes, DC 
and macrophages and has a pivotal role in shaping and linking the innate and adaptive 
immune systems
4
. It is also an important mediator of inflammation, by inducing 
vasodilation, fever and pain. Leukotriene B4 is a potent chemoattractant and activator of 
neutrophils with essential roles in inflammatory disorders. Conversely, lipoxins are 
potent anti-inflammatory agents active in nanomolar concentrations that inhibit 
migration of neutrophils to the inflamed tissue and promote recruitment of monocytes 
that will remove the cellular debris of the battle
5
. There is a time course formation of 
these mediators with switch from pro-inflammatory derivatives in the beginning to anti-
inflammatory towards the resolution phase.  
However, when the signals suppressing inflammatory reactions are defective, 
inflammation proceeds uncontrolled and ceases to be beneficial, resulting in pathogenic 
chronic disease states, such as rheumatoid arthritis. The driving force behind chronic 
inflammation is a perpetual activation of the adaptive immune system through cytokine 
feedback loops.  
A remarkable feature of the immune system is its ability to react to a multitude of 
pathogens while avoiding attack on self structures. This is achieved through a 
thoroughly controlled process called immune tolerance by which the cells of the 
immune system get acquainted to the organism’s own antigens and are “taught” to 
discriminate self from non-self. Immune tolerance takes place centrally in the thymus 
and bone marrow (central tolerance) and in periphery as a second fine-tuning process 
(peripheral tolerance). Failure in these mechanisms with subsequent dysregulation of 
immune reactions results in loss of tolerance against self structures and autoimmunity. 
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Autoimmunity is thus defined as an immune response towards self antigens. Cells of 
the innate and adaptive immune systems become activated and turn on unrelenting 
inflammatory pathways, in such a way that the inflammation becomes chronic and 
complete resolution is very difficult to achieve. 
Autoimmune conditions, such as rheumatoid arthritis, occur commonly and affect at 
least 1-2% of people in developed countries
1
. They feature chronic inflammation in one 
or more organs and they typically present with autoantibodies against organ-specific or 
ubiquitous antigens. 
RHEUMATOID ARTHRITIS 
Rheumatoid arthritis is a chronic systemic inflammatory disease affecting 0.5- 1% of 
the population worldwide
6
, with a female preponderance and a peak incidence during 
the fourth decade of life 
7
. Initially receiving its current name in the mid 19
th
 century 
and being officially recognized as a distinct disorder even later, this disease has been 
around since several thousand years
8
. It affects primarily synovial joints, with chronic 
inflammation, subsequent destruction and gradual functional disability, and is 
associated with substantial systemic co-morbidities.  
Clinical features, laboratory findings and diagnosis 
Rheumatoid arthritis usually has a gradual onset, starting with joint inflammation and 
tenderness, pain aggravated by rest and relieved by exercise, and morning stiffness. 
Fatigue, loss of appetite and low-grade fever may also be part of the general disease 
manifestations. Systemic features with pericarditis, pleuritis, lung fibrosis, vasculitis, 
rheumatoid nodules may co-exist at onset or become apparent during disease course. 
However, aggressive and efficient initial treatment has led to a lower frequency of 
extra-articular involvement
9
. Important co-morbidities in RA patients, such as risk 
increase for lymphoma and particularly cardiovascular disease, greatly reduce their life 
expectancy. In fact, cardiovascular diseases account for about half of the deaths in 
patients with RA 
10
.  
It is well-known that a large proportion of patients present autoantibodies in the 
blood. Rheumatoid factor is historically the most established autoantibody present in 
RA patients
11
. It is directed towards the Fc portion of immunoglobulins and its 
discovery led to the logical view that RA is an autoimmune disease.  However, it has 
low specificity for the disease, since it is also present in healthy individuals (5%, 
frequency increasing with age) and patients suffering from other chronic inflammatory 
disorders
12
. More recently, anti- citrullinated peptide antibodies (ACPA) have 
demonstrated higher specificity for RA
13
. Both antibodies are clinically useful 
prognostic markers and predict a more aggressive, destructive course, in particular 
when associated with shared epitope
14,15
.  
Since there is considerable heterogeneity in clinical manifestations, a set of criteria
16
 
was defined by the American College of Rheumatology (ACR) in 1987 to be used for 
differentiating RA from other inflammatory arthritides (Table 1).  
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Table 1. The 1987 American College of Rheumatology classification criteria for RA 
1. Morning stiffness for at least 1 h 
2. Arthritis in three or more joint areas with soft tissue swelling and fluid 
3. Arthritis of hand joints (wrist, metacarpophalangeal or proximal 
interphalangeal joint) 
4. Simultaneous involvement of the same joint areas on both sides of the body 
5. Rheumatoid nodules 
6. Rheumatoid factor 
7. Typical radiographic changes on hand and wrist radiographs (erosions or bony 
decalcification) 
Criteria 1- 4 should be present for at least 6 weeks. For classification as RA, at 
least four criteria must be fulfilled. (Adapted from Arnett et al. Arthritis Rheum 1988) 
However, these criteria were developed to define established disease and provide a 
standard for recruitment into clinical trials
17
. The knowledge accumulated in the past 
years about pathogenesis and more specific serological markers as well as the success 
of early intervention with potent drugs has re-defined the strategy and goals for 
treatment and justified the need to identify patients at an early stage. Ideally, therapy 
should be instituted early in the disease development before erosions are apparent in 
order to prevent joint destruction
18,19
. Largely regarded as unsatisfactory for diagnosing 
purposes, these criteria were recently revised and new criteria have been proposed
20
 
(Table 2) as well as recommendation for pharmacological treatment. 
Table 2. The 2010 ACR/ EULAR classification criteria for RA 
 Score 
A. Joint involvement 
1 large joint 
2-10 large joints 
1-3 small joints 
4-10 small joints 
>10 joints  
 
0 
1 
2 
3 
5 
B. Serology 
Negative RF and negative ACPA 
Low positive RF or low positive ACPA 
High-positive RF or high-positive ACPA 
 
0 
2 
3 
C. Acute phase reactants 
Normal CRP and normal ESR 
Abnormal CRP or normal ESR 
 
0 
1 
D. Symptoms duration 
<6 weeks 
>6 weeks 
 
0 
1 
Add scores in categories A-D. A score > 6/10 is needed for a definite RA diagnosis. 
For criteria B and C at least 1 test result is needed for the disease to be classified as 
RA (Adapted from Aletaha D. et al. Ann Rheum Dis 2010). 
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Disease activity score, often counted in 28 joints (DAS28), along with European 
League Against Rheumatism (EULAR) criteria are validated measures for disease 
activity, most commonly used to evaluate the patient’s response to treatment in clinical 
trials
21
. These measures differ in that DAS evaluates the changes in diseases activity, 
while EULAR criteria take into account both the changes and the level of disease 
activity attained.  DAS or DAS28 combine information from swollen joints, tender 
joints, the acute phase response – measured either as C reactive protein or erythrocyte 
sedimentation rate - and general health. The EULAR response criteria classify 
individual patients as non-, moderate, or good responders. 
Healthy and rheumatoid synovium 
The healthy synovium is a thin membrane, two to three cells thick, divided in two 
anatomical and functional distinct regions, the intimal lining layer and the sublining 
layer. The lining layer is in contact with the joint space and the lubricating synovial 
fluid and is composed of macrophage-like synoviocytes (type A) and fibroblast-like 
synoviocytes (type B) in a loose extracellular matrix. It is an avascular structure lacking 
a basement membrane. In the sublining layer, few fibroblasts, adipocytes and scattered 
mononuclear cells are interspersed with vessels in a loosely organized connective 
tissue
7
. 
 In the established disease there is a marked proliferation of synoviocytes in the 
lining layer contributing to pannus formation, a structure with aggressive potential that 
drives the destructive process at the cartilage-bone junction. In the sublining, there is 
massive infiltration with mononuclear cells, especially macrophages, T and B cells and 
increased vascularization. In about one third of patients ectopic formation of lymphoid 
structures can be seen in the synovium
22
, some resembling germinal centers where 
maturation of B and T cells is thought to occur. Persistence of the antigen triggering the 
disease in the tissue is a critical element required for induction of these structures. 
Formation of lymphoid aggregates is not disease or tissue specific but rather the 
outcome of chronic inflammation 
23
. 
Ethiopathogenetic mechanisms 
The etiology of the disease still remains unknown, but both genetic and environmental 
factors have emerged as having substantial influence in the development of RA
19
. A 
role for genes in the pathogenesis was revealed by twin studies in which the genetic 
component was shown to account for about 60% in the development of the disease 
24
. 
Genetic evidence that the immunological response plays a critical role in the 
pathogenesis dynamics comes from association between RA occurrence and genes 
involved in immune regulation. The single most important genetic risk factor for RA is 
linked to the MHC class II locus
25
. The HLA DRB1 alleles code for a common 
aminoacid sequence – called the shared epitope - located in the antigen-binding region 
of the HLA molecule. A second identified genetic susceptibility gene in Caucasian 
population is PTPN22
26
 which encodes a tyrosine phosphatase involved in T cell and B 
cell signaling
27
. These genetic associations, together with the presence of MHC-
expressing antigen presenting cells
28
 and T cells
29
 in the rheumatoid synovium has 
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strengthened the argument for the contribution of MHC-dependent T-cell and B cell 
responses in the pathogenesis of the disease.  
Accumulating data have indicated that cigarette smoking is the most important 
environmental factor increasing the risk of RA
30
, particularly in rheumatoid factor –
positive and ACPA-positive patients
31,32
. Importantly, there is a major interaction 
between smoking and HLA DR risk alleles, with up to 20 times increased risk to 
develop the disease in genetically susceptible smoking individuals
33
.  
The pathogenesis of RA is complex and yet far from being completely deciphered 
despite extensive research efforts. The evidence so far points to a pathogenic 
mechanism whereby in genetically susceptible individuals exposure to environmental 
insults (smoking) contributes to post-translation modifications in proteins 
(citrullination) that trigger dysregulated immune responses and breach of tolerance
34
. 
Additional un-identified trigger events may then contribute to joint localization, 
activation of immune responses, subclinical local inflammation and finally clinically 
apparent disease
19
. This series of events is particularly true for the subsets of RA 
patients displaying anti-CCP antibodies, whereas the ACPA negative subset has not 
been demonstrated to be associated to HLA locus or any established environmental 
factors. There are however studies suggesting different genetic and environmental 
profiles for ACPA-negative RA
19
. So far, accumulating data suggests the existence of 
two subsets of disease with different pathogenesis and prognostic factors, effects of 
environmental exposure and genetic susceptibility.  
There are multiple mechanisms for synovial inflammation, with continuous 
activation of cells of the adaptive immune response by the multitude of cytokines 
present in the synovial compartment.  
Cellular network 
Interaction and reciprocal regulation within an extensive network of cells characterizes 
the rheumatoid synovium. Below I will describe some features of the main cell 
populations. 
Monocytes/ macrophages 
The role of monocytes and macrophages (MΦ) in the RA pathogenesis is underlined by 
their large number in the inflamed synovium, their broad pro-inflammatory and 
destructive potential and most importantly, by the correlation between radiographic 
progression of joint destruction and the degree of synovial macrophage infiltration 
35
. 
Moreover, the degree of clinical improvement and response to treatment correlates well 
with a decrease in sublining MΦ for different therapeutic approaches 36. Activated 
synovial MΦ may in fact represent a link between synovial inflammation and joint 
destruction. 
There are two types of macrophages in the RA synovial tissue, the intimal lining 
macrophage-like synoviocytes and the sublining macrophages, that have migrated as 
monocytes from the circulation to the synovial compartment and are diffusely 
distributed throughout the synovium,. Both types have multiple and powerful biological 
functions underscored by their antigen presenting function, scavenging of cellular 
debris, chemotaxis through MΦ-derived cytokines and chemotactic factors and 
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formation of lipid mediators such as prostaglandins and leukotrienes
37
.They express 
several markers of the resident macrophage population including CD68, CD163 and 
CD14
38
. Owing to their plasticity, cells of the myelomonocytic lineage can be 
influenced by the cytokines/ growth factors balance in the microenvironment and can 
differentiate into several cell types that are critically involved in disease, as osteoclasts 
or dendritic cells. Upon TNF or IL-1β stimulation, synovial fibroblasts and activated T 
cells upregulate RANKL (receptor activator of nuclear factor κ B ligand) expression on 
their surface which can then engage its receptor (RANK) on the surface of monocytes 
and drive them into osteoclastogenesis
39
. Molecules relevant for osteoclast 
differentiation, such as macrophage colony stimulating factor, IL-17 and TNF, are 
abundant in the synovial tissue. 
Macrophage activation and subsequent cytokine production is likely to occur 
through Toll-like receptors, known to promote and perpetuate inflammation. In RA, 
functional TLR2 and TLR4 are expressed in synovial and peripheral blood 
mononuclear cells. Their expression is upregulated by local cytokines. While being 
producers of key pro-inflammatory cytokines such as TNF, IL-1, IL-6, IL-12, IL-23, 
MΦ also secrete anti-inflammatory factors - IL-10 and IL-1RA. Most of the TNF and 
IL-1 in RA is produced by MΦ in the synovial membrane 37 and in particular at the 
pannus-cartilage junction. In addition, MΦ can secrete matrix metalloproteinases 
(MMP) 1, 2 and 9 and cathepsins that contribute to cartilage degradation and a series of 
chemokines that attract other immune cells 
37,40
.  
Fibroblasts 
Fibroblast-like synoviocytes (FLS) in the rheumatoid synovium have different 
phenotypes in the lining and sublining regions. Intimal FLS, which are responsible for 
pannus invasion of neighboring structures, have unique invasive and aggressive 
features that differentiate them from other fibroblasts
38
. They display a unique 
phenotype resembling transformed cells which may be either an inherent feature of RA 
FLS or the result from an extensive exposure to cytokines. By expressing adhesion 
molecules they may also promote binding of mononuclear cells to the tissue. Since 
limited fibroblast proliferation was demonstrated in RA, the accumulation of FLS is 
thought to result from low apoptosis and increased survival promoted by the synovial 
milieu. Platelet-derived growth factor, basic fibroblast growth factor and in particular 
TNF and IL-1 may contribute to the synovial hyperplasia and activation. There is a 
paracrine/ autocrine network whereby activated macrophages produce pro-
inflammatory factors that in turn activate FLS to produce their own arrays of mediators, 
sustaining positive feedback loops. They form chemokines and cytokines necessary for 
survival and activation of B cells and T cells (BAFF, IL-17) and massive amounts of 
matrix enzymes (MMPs, cathepsins) that degrade cartilage as well as their inhibitors. 
At the same time, FLS can express RANKL in response to inducing agents and 
contribute to formation of osteoclasts from their precursors. This indicates a central role 
for synovial fibroblasts in integrating and linking the inflammatory reaction with the 
destructive phase in the RA pathogenesis. 
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T cells 
The hypothesis that T cells are the major drivers of the dysregulated immune response 
and subsequent inflammatory effector mechanisms in RA is sustained by several 
observations: 1) T cells are found in high number in synovium
29
; 2) the disease is 
associated with certain MHC class II loci
41
; 3) the disease can be reproduced 
experimentally by transfer of T cells and many animal models of the disease are T cell 
dependent
42,43
. 
In the synovial tissue, T cells are identified as CD3 positive and belong to one of the 
following subsets: CD4+ T helper cells, CD8+ cytotoxic T cells, or regulatory T cells, 
with a predominance of CD4+ cells 
38,44
. The cytokines present in the environment 
dictate the direction of differentiation towards a particular T cell lineage. These 
pathways antagonize and cross-talk with each other through cytokines and are in certain 
cases mutually exclusive. The T helper (Th) phenotypes differ by their effector 
functions and are defined by a distinct pattern of cytokines formed. As such, the Th1 
subset mediates cellular immunity and is defined by IFNγ secretion; the Th2 is 
involved in humoral immunity and forms mainly IL-13 and IL-4, while Th17 is the 
newest member of this family identified through its signature cytokine, IL-17.  
Data accumulated over the last years implicate Th17 cells as crucial promoters of 
autoimmunity in RA
45
. Earlier Th1 hypothesis stated that the rheumatic milieu 
promotes the polarization of T cell subsets towards a Th1 predominant phenotype
46
. 
There has been a shift in hypothesis during the last years and Th17 cells represent now 
the new paradigm of T cell contribution to RA pathogenesis.  
Regulatory T cells are a subset of T cells detected in the synovial tissue and fluid of 
RA patients and their role is to maintain self-tolerance by regulation of immune 
responses and prevention of autoimmunity. However, these cells have impaired 
functions in RA and low suppressor ability
47
 which can be restored by treatment with 
TNF inhibitors
47,48
. 
B cells 
The B cell pathogenic role in autoimmune disorders has historically been attributed to 
their secretion of autoantibodies that would drive inflammatory cascades locally either 
in soluble form or as immune complexes. We know now that, apart from that, B cells 
are important antigen presenting cells and provide critical signals that regulate the 
activation and expansion of T cells in the synovium
49
. B cell-derived cytokines regulate 
dendritic cell activation and are important for the formation of ectopic lymphoid 
structures and their maintenance, as for instance lymphotoxin β 50. In addition, B cells 
release cytokines (such as IL-6, IL-10) that provide feedback via interaction with T 
cells and macrophages. The interaction between B cells and T cells provides grounds 
for a potential vicious circle to sustain autoimmunity. A distinct subset of B cells 
producing IL-10 in mice were shown to have an immunoregulatory role in 
autoimmunity
51
, possibly by modulating macrophages and dendritic cells or restoring 
the cytokine balance 
52
. 
The lymphocyte infiltrate in RA tissue has several patterns of organization, from 
diffusely distributed or loosely aggregated to ordered structures resembling germinal 
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centers
23
. The formation of ectopic germinal centers seems not to be a specific feature 
of RA. It is present in several chronic inflammatory diseases and is thus the result of 
sustained inflammatory processes rather than being causative
22
. A number of factors 
produced by fibroblasts and dendritic cells, such as chemokine (CXC) ligand 12 and 
CXC13, BAFF, TNF and interferon (IFN) γ contribute to accumulation of B cells to the 
synovium and organization of these lymphoid structures
52
. In addition, B cells are 
critical in sustaining T cell activation in RA patients exhibiting ectopic lymphoid 
structures
53
. The evidence for pathological involvement of B cells in RA has come 
from experimental mouse models; autoantibodies seem to play a role in initiation of 
pathological events
54
 while lack of B cells prevents the induction of arthritis and results 
in impaired T cells response in CIA
55
. In humans however, the key role of B cells in 
orchestrating the immune response in RA has become evident with the benefit achieved 
by B cell depleting therapy. 
Neutrophils 
Neutrophils are the largest cell population in the synovial fluid but remarkably few of 
them are found in the tissue. They are the first to invade the synovial joint, followed by 
monocytes 
56
, and contribute to the early pathogenesis phase by releasing reactive 
oxygen species and proteases that damage cells and tissues. By degrading cytokines or 
activating their precursors, they have the potential to regulate or amplify inflammation 
by recruiting and activating other immune cells. The impairment in apoptosis of 
synovial and peripheral blood neutrophils that can be seen early in the disease course 
can be reversed by methotrexate treatment
57
. The most powerful chemotactic agent for 
neutrophils is LTB4
58
, found at high levels in synovial fluid
59
. 
Dendritic cells 
Dendritic cells (DC) have essential roles in the orchestration of immune reaction in RA, 
since they are initiators and modulators of the immune response. Through their potent 
antigen presentation ability, they stimulate naïve T cells, direct effector cell functions 
and polarize the T cell repertoire towards the Th1, Th2 or Th17 phenotypes. Myeloid 
DC are considered especially important in promoting synovial inflammation and it is 
believed that they drive the activation of autoreactive T cells; plasmacytoid DC may 
have dual roles, in regulating antibody production and acting as tolerance inducers
60
.  
Inflammatory mediators 
A large number of cytokines, chemokines, growth factors and lipid mediators promote 
constant recruitment and activation of cells sustaining synovitis and the processes 
leading to tissue destruction. This complex network of mediators is characterized by 
redundancy, with many cytokines having similar properties, and by activation of 
multiple signaling cascades with diverse biological effects
61
. There is a large number of 
monocyte- and fibroblast-derived mediators
62
 which include IL-1, TNF, IL-6, IL-8, IL-
10, IL-15, IL-18, GM-CSF, MIF, prostaglandins and leukotrienes, to name just a few. 
Lymphocyte-derived cytokines, such as IL-2, IFNγ, IL-5, IL-13, but not IL-17, are 
found only at low levels in the synovial fluid, reflecting reduced T cell immune 
responses, possibly as a consequence of prolonged exposure of lymphocytes to 
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inflammatory stimuli 
63
.  A dominant role for TNF in driving the inflammatory cascade 
in rheumatoid synovial tissue became evident with the introduction and successful use 
of TNF blockers
61
. The concept emerging is that TNF is an early and important trigger 
of downstream inflammatory mechanisms and feedback loops within a network of 
immune and non-immune cells and cytokines. 
TNF is released as a soluble cytokine after being cleaved from its membrane 
precursor from a variety of cells, mostly synovial macrophages and fibroblasts in RA. 
Binding to either of the two receptors – TNF receptor 1 (TNFR1) and TNFR2 leads to 
activation of NF-κB or to apoptosis, via two distinct pathways. TNFR1 is virtually 
expressed on all cell types whereas TNFR2 is inducible and mostly found on 
hematopoietic cells. TNF induces production of other mediators, such as IL-1, IL-6, 
INFγ, PGE2; these in turn can induce regulatory positive or negative feedback loops 
64
. 
Major eicosanoids in the synovial fluid are PGE2 and LTB4, although other 
prostanoids, leukotrienes and anti-inflammatory lipoxins are also present. They will be 
discussed in detail later in this book. 
Therapeutical strategies 
There are several treatment options for RA, but despite significant therapeutic advances 
none has proven to cure the disease. Accumulating evidence over the past decade 
demonstrates that the earlier and most extensively the degree of disease activity is 
reduced, the better the outcomes will be. 
Non-steroidal anti-inflammatory drugs (NSAIDs) 
NSAIDs provide symptom relief by blocking the formation of pro-inflammatory 
prostaglandins acting on the upstream enzymes, cyclooxygenases (COX) 1 and COX-2. 
Although they reduce pain and inflammation and improve joint mobility, there is no 
evidence that they slow down the disease progression. As such, they are prescribed as 
adjuvant along with more potent medication such as synthetic or biological disease-
modifiers. Inhibition of constitutive COX-1 by non-selective NSAIDs may cause 
potential serious side effects. Even the selective COX-2 inhibitors are employed with 
caution due to increased cardiovascular events reported with their use
65
. 
Glucocorticoids 
Glucocorticoids (GC) have been successfully used for decades in RA patients either 
systemically or as intra-articular injection to suppress disease activity or reduce local 
symptoms such as inflammation, swelling and pain. However, important side-effects, 
such as osteoporosis and diabetes, limit their long-term systemic use.  
In practice, oral GC are usually used as a bridging therapy to control disease activity 
between the time a DMARD is initiated to the time it starts becoming clinically 
effective. Also, low-dose GCs are often added to DMARDs for their joint-protective 
effect
18
. Although they have a negative impact on bone mineral density with increased 
risk for fracture
66
, there is also evidence that low dose GC in combination with anti-
rheumatic treatment yields better clinical outcomes and less radiographic damage
67-69
. 
This is most likely due to better control of the inflammatory status which per se has 
deleterious effects on the bone. Intra-articular GCs are used as efficient adjuvant 
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treatment 
70
and their beneficial actions in RA are related not only to dampening 
inflammatory-related symptoms but also to protective bone effects by decreasing 
RANKL
71
. The latter is the most important mediator of osteoclast-dependent bone 
degradation and is induced in activated T cells and fibroblasts by TNF, IL-6, IL-17, 
PGE2, and possibly other factors
72
. 
Their broad anti-inflammatory systemic effects are mediated through genomic 
mechanisms (activation or repression of gene transcription) and non-genomic 
mechanisms (independent of de novo protein synthesis)
73
. Repression of target genes 
by the GC-receptor complex is responsible for suppression of adhesion molecules 
expression, inflammatory cytokines, growth factors, prostanoids and other mediators, 
largely through inhibition of NF-κB-induced pro-inflammatory genes 74,75. In addition, 
the GC-receptor complex can bind to specific nucleotide sequences termed GC-
response elements and activate transcription of genes involved in resolution of 
inflammation, such as IL-10 and IL-1RA. Indirectly they can turn on mechanisms that 
limit inflammatory response through for example annexin 1 in innate and adaptive 
immune cells. Through non-genomic effects, GCs modulate the activation or 
responsiveness degree of cells involved in inflammatory reactions.  
Disease-modifying anti-rheumatic drugs (DMARDs)  
Disease-modifying anti-rheumatic drugs (DMARDs) are compounds able to retard 
progression of disease and slow down the joint damage. Apart from the traditional 
synthetic DMARDs that have been the standard of care in RA, the past two decades 
assisted to the emergence of a new class of potent drugs, so called biologics or 
biological DMARDs that comply to the definition of compounds halting disease 
progression and structural destruction
64
. 
 Methotrexate 
Methotrexate is the mainstay therapy in RA and the first-line choice in the management 
of this disease
76
. It was originally developed to treat malignancies by antagonizing 
cellular folate and interfering with DNA synthesis. Although antiproliferative and 
immunosuppressive at high doses, there is increasing evidence from in vivo, in vitro 
and clinical data that in fact the anti-inflammatory effects of low-dose methotrexate – 
as seen in RA treated patients - are mediated through adenosine release. Other 
mechanisms that may be operating are suppression of T cell proliferation and increased 
apoptosis and modulation of cytokine formation and humoral responses
77
. 
Methotrexate is an inhibitor of dihydrofolate reductase that forms tetrahydrofolate 
(THF) and as a consequence, of folate-dependent enzymes. Inhibition of dihydrofolate 
reductase decreases the availability of THF, interfering with DNA synthesis. At the 
same time, accumulation of upstream products results in increased AMP formation and 
subsequently adenosine. Supporting this notion, in a mouse air pouch model, 
methotrexate raised adenosine while reducing TNF levels in inflammatory exudates 
and reduced leukocyte trafficking
78,79
. Furthermore, the anti-rheumatic effects are 
diminished in patients treated with low doses methotrexate taking adenosine receptor 
antagonist
80
. Binding of adenosine to A2A and A3 receptors is thought to mediate many 
of methotrexate’s anti-inflammatory effects81, a concept arising from studies in 
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knockout mice. The beneficial effects in RA mediated by this pathway include 
inhibition of lymphocyte proliferation and production of TNF, IL-8, IL-12 and IFNγ. It 
is known that mehotrexate suppresses TNF production by T cells and macrophages
82
  
and IL-6 levels in RA patients, while IL-4 and IL-10 are increased in peripheral blood 
monocytes
83,84
, suggesting that methotrexate adjusts the balance between Th1 and Th2 
cytokines. Moreover, by interfering with binding of IL-1 to its receptor
85
 or reducing 
synovial IL-1 levels
86
, methotrexate may inhibit the cellular responses to IL-1, resulting 
in interruption of inflammatory circuits. 
In RA patients, methotrexate is usually administered once weekly in doses ranging 
from 7.5 to 25 mg/week, orally or as a subcutaneous injection. Its efficacy as 
monotherapy and ability to increase the efficacy of biological therapy, combined with 
low toxicity profile makes it an anchor drug in RA. 
Other DMARDs, including leflunomide, sulfasalazine, injectable gold and 
hydroxycloroquine, are recommended as second line approach if there is 
contraindication (or intolerance) to methorexate
87
. In addition, immunosuppressive 
drugs such as azathioprine, cyclosporine A or cyclophosphamide have provided 
evidence of efficacy in refractory cases.  
Biological therapy 
Biological drugs are a modern class of therapeutic agents derived from biologically 
active molecules and designed to modulate specific immune or inflammatory pathways.  
 TNF blockers 
The introduction of TNF blockers in clinical use has revolutionized the treatment of RA 
to the point where it is now conceivable to aim at remission of disease rather than low 
disease activity. The great efficacy seen in many patients upon treatment, with marked 
amelioration of symptoms, reduced signs of inflammation and reduced systemic 
inflammatory parameters translate into a reduced disease activity and increased joint 
function
64
. 
Perhaps the most important clinical benefit of TNF antagonists is the prevention of 
cartilage and bone destruction 
88-90
 and in some cases even reversal of erosions. The 
greatest efficacy is seen in combination therapy of TNF antagonist with methotrexate
90
, 
probably owing to complementary mechanisms of action. The mechanism by which 
TNF blockers inhibit erosion progression relies on reduced synovial macrophage 
number
91
 and as a consequence reduced number of osteoclasts, diminished blood levels 
of MMPs
92
, regulation of RANKL and increased osteoprotegerin levels
93
 – a decoy 
receptor for RANKL that blocks its action. 
The dominant feature of anti-TNF action is diminished cellularity and leukocyte 
trafficking in the synovial compartment, likely occurring as a result of reduction in 
adhesion molecules, chemokines and cytokines such as IL-6, IL-1, IL-8, macrophage 
chemoattractant protein 1 and VEGF – a marker for increased angiogenesis in RA - 
both in synovial tissue, serum and blood 
61,64
. Also, the apoptosis of monocytes/ 
macrophages in synovial fluid may be an additional mechanism
94
. On the immune 
system level, TNF antagonists normalize the dysfunction in regulatory T cells by 
increasing their number and reversing their anergic phenotype
47
. 
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There are so far three TNF inhibitors in common clinical use and two more newly 
arrived on the market. Infliximab was the first out to be tested and is a human – mouse 
chimeric antibody containing the variable regions of a mouse anti-TNF antibody 
attached to the human constant anti-TNF antibody regions. It targets soluble and 
membrane bound TNF and is administered as an intravenous infusion. Etanercept is a 
soluble dimeric fusion construct consisting of the TNF receptor p75 bound to the Fc 
portion of a human IgG; it can bind soluble and membrane bound TNF as well as 
lymphotoxin (formerly known as TNFβ) and is administered weekly as subcutaneous 
injection. Adalimumab is an entirely human IgG monoclonal antibody used once every 
second week as subcutaneous injection. In addition, two new TNF blockers have been 
approved during the last year, golimumab and certolizumab pegol; they seem to share 
similar efficacy profile and risks as the original members of this group
95
. 
 B cell depleting therapy 
Rituximab is a chimeric IgG1 monoclonal antibody directed against CD20, a 
transmembrane molecule expressed on the B-lineage cells from the pre-B stage in the 
bone marrow throughout B cell development and differentiation in the periphery up to 
pre-plasma stage. Importantly, plasmablasts and antibody-secreting plasma cells do not 
exhibit this marker. It achieves B cells killing mainly through Fcγ receptor antibody-
dependent cell-mediated cytotoxicity
96
. However, marginal-zone B cells in the spleen 
and germinal centers B cells are resistant to depletion, probably due to protective niches 
where the antibody does not gain access 
97
.  
Despite complete depletion of circulating B cells in nearly all patients, lasting 
usually for about 4-6 months, there is a significant proportion of patients resistant to 
therapy that do not achieve significant clinical improvement
98,99
. It was shown that 
synovial B cells may persist in the tissue despite complete depletion in the circulation 
and persistence of plasma cells in the synovial tissue correlated with lack of response to 
treatment
100,101
. It is common that patients remain in remission for longer time than the 
depletion phase, but the relapse seems not to be related to peripheral re-population with 
B cells
100
.  The observation that B cells in the synovial tissue are not depleted to the 
same extent as circulating B cells and that early re-emergence of memory B cells into 
circulation associates to poor clinical response
102
 underscores the importance of 
depleting tissue autoreactive B cells.  
 Levels of RF and ACPA titers decrease slowly with treatment
100
, sometimes to 
undetectable levels, reflecting probably the decrease in short-lived plasma cells derived 
from targeted B cells that are responsible for autoantibody production
96
. In addition, 
reduction in follicular lymphoid structures size and number following treatment mirrors 
the decrease in synovial B cells and macrophages and reflects decreased synovitis
103
. 
The mode of action of rituximab suggested by recent studies presumably involves 
depletion of tissue autoreactive B cells, with several consequences - decreased 
autoantibody and immune complex formation, reduced cytokine production, followed 
by reduced macrophage load and decreased synovial inflammation
104
. 
Newer B cell depleting drugs are in late stage clinical development; ofatunumab is a 
fully humanized anti-CD20 antibody expected to have similar efficacy to rituximab. 
Belimumab and atacicept target survival factors (BAFF and APRIL) or their receptors 
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involved in survival and differentiation of B cells. Clinical evaluation trials are ongoing 
to assess their efficacy and safety profiles. 
There are a number of other biological drugs in clinical use: anakinra blocks IL-1 
receptor and has some efficacy in RA, although far from the one achieved by TNF 
antagonists
95
.  Both tocilizumab blocking the IL-6 receptor and abatacept targeting the 
co-stimulatory pathway for T cells show similar efficacy to TNF blockers; while 
tocilizumab possibly induces remission in a higher proportion of patients, abatacept-
treated patients show fewer infections than infliximab
105
. They are usually used in cases 
where other biological therapies have failed and the recommendation is as for TNF 
inhibitors, to be associated with methotrexate for increased efficacy. Also, methotrexate 
prevents formation of anti-drug antibodies
106
. 
Although still far from achieving the goal of inducing stable drug-free remission, 
studies on the immunological pathways targeted by anti-cytokine therapies and 
identification of tissue and serum markers associated with response or resistance to 
treatment provide insights into new and possibly more efficient drug targets. 
EICOSANOIDS 
Eicosanoids are a class of lipid mediators with a wide variety of biological activities 
stemming primarily from arachidonic acid, a twenty-carbon fatty acid. The word 
eicosanoid is derived from the Greek eicosi meaning 20. The main classes of 
eicosanoids - prostaglandins, leukotrienes and lipoxins - are synthesized by 
cyclooxygenases and lipoxygenases from fatty acid-derived precursors. The first step in 
the synthesis of eicosanoids is catalyzed by phospholipase A2 (PLA2) that releases 
arachidonic acid (AA) from membrane phospholipids upon cell stimulation, usually by 
cytokines, growth factors, mechanical stress or other noxious stimuli. 
The PLA2 family comprises over 25 members grouped in three classes: secretory 
PLA2, calcium-dependent (also called cytosolic) and calcium-independent intracellular 
PLA2. They have diverse roles in host defense and inflammation, with some 
contributing as pro-inflammatory and other to ameliorate inflammation
107
.  
Cyclooxygenase pathway 
Prostaglandins (PG) arise through sequential actions of cyclooxygenase (COX) 
enzymes which initially form an intermediate unstable PGH2, rapidly converted by 
terminal synthases to the bioactive lipid compounds, namely PGE2, PGD2, PGF2α, PGI2 
(often called prostacyclin) and tromboxane A2
108
. 
Prostaglandin E2 
PGE2 is the most ubiquitously produced prostaglandin under physiological and 
pathological conditions and regulates fundamental biological processes through broad 
spectrum effects. It is involved in regulation of immune responses, vascular pressure 
control, integrity of the gastro-intestinal tract mucosa, kidney perfusion and female 
reproduction 
109
. Apart from its homeostatic roles, PGE2 exerts key biological functions 
in inflammation, pain, fever regulation and tumorigenesis
110
. 
   15 
PGE2 exerts its functions by binding to one of its four receptors named EP1 through 
EP4, all G-protein coupled receptors (GPCRs) that constitute the prostanoid receptor 
family within the GPCR superfamily
111
. The main cellular transduction pathway in EP2 
and EP4 involves signaling via rising intracellular cAMP, in EP3 via decrease in 
cAMP, while in EP1 is mediated through increase in intracellular calcium 
concentration
111
. The variable tissue distribution and cell localization of the receptors 
determine cell-specific effects of PGE2 signaling depending on the local cellular 
environment.  
 
Fig. 1 Simplified version of the eicosanoid pathway with relevance to pathways 
investigated in my studies.  
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There are extensive studies on PGE2 in acute and chronic inflammatory conditions. 
The ability to regulate the immune response at various levels, from cells involved in 
innate immunity to antibody synthesis makes PGE2 an important contributor to 
immune- mediated diseases. 
PGE2 formation is highly increased during inflammatory conditions and it is fair to 
say that it mediates all signs of inflammation. Vasodilation with increased blood flow 
resulting in local swelling, heat and redness, peripheral nociception with hyperalgesia 
and in some cases promotion of tissue destruction can all result from PGE2 release
2,109
. 
PGE2 is known to modulate the activity of antigen presenting cells (APC), such as 
dendritic cells and macrophages, and shape the outcome of the adaptive immune 
response by influencing the cytokine balance in the microenvironment
4
. Depending on 
the site of encounter, PGE2 exerts stimulatory or inhibitory effects on DC. In periphery, 
PGE2 activates and promotes migration of DC to the lymph nodes, but once there, it 
inhibits their maturation and antigen presentation ability. PGE2 has been implicated in 
inhibition of T cell proliferation owing to decrease in IL-2 production 
112
 but also in 
modulation of T cell apoptosis
113,114
. In fact, it plays important roles throughout the life 
of T cells, from thymic selection to proliferation, cytokine secretion and apoptosis. In 
general, it was considered that PGE2 may favor a Th2 response over Th1 by inhibiting 
IFNγ and IL-2 secretion, while sparing IL-4 and IL-5 formation115. However, this 
concept arising from in vitro studies was challenged recently by investigations showing 
that physiologically low PGE2 concentrations facilitate a Th1 response in mouse
116
. 
Also, PGE2 can synergize with IL-23 facilitating Th17 cell expansion 
117
 and promotes 
accumulation of antigen-specific Th1 and Th17 cells in lymph nodes in mouse 
autoimmune encephalomyelitis, mainly through EP4 receptors
118
. Indeed, increasing 
focus on Th17 cells as drivers of autoimmune reactions has led to new insight into the 
role of PGE2 to promote Th17 polarization of the immune response. PGE2 regulates the 
cytokine expression pattern by DC and can bias the T cell repertoire towards Th1 or 
Th17 dominance
115
. Moreover PGE2 mediates joint inflammation and damage in mouse 
collagen-induced arthritis (CIA) through IL-23/IL-17 axis
119
.  
In B cells, PGE2 assumes inhibitory roles in the lineage development, as mice 
treated with PGE2 show fewer B cell precursors in their bone marrow 
120
. In the mature 
B cell, PGE2 has immunosuppressive roles and represses proliferation of B cells 
through the prostaglandin EP4 receptor gene 
121
. It is known that activated, but not 
resting peripheral blood B cells can form PGE2 through COX-2 upregulation
122
.  
In activated macrophages, PGE2 dampens production of TNF, IL-1 and IL-12 and 
increases IL-10
123,124
. On the other hand, LPS-stimulated macrophages are an important 
source of PGE2; there is also an autocrine feedback regulation whereby PGE2 can 
upregulate COX-2 and its own formation
124,125
. 
With relevance to rheumatoid arthritis, PGE2 has a pivotal role in local bone 
remodeling and there are many studies underlinig its role in bone-resorptive diseases
126
. 
Bone is a living tissue with osteclasts removing old bone and osteoblasts replacing it 
with new one. Resorption is dependent on interaction between RANKL on osteoblasts, 
activated T cells or fibroblasts and RANK on osteoclast precursors
72
. In addition, 
osteoprotegerin (OPG) can prevent the formation of osteoclasts by binding to RANKL. 
There is not a clear consensus as to whether PGE2 promotes anabolic or catabolic 
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processes in the bone and in fact the net effect may depend on the type of receptors 
locally present. Both EP2 and EP4 receptors mediate bone resorption in response to 
PGE2 in mice, since lack of these receptors greatly reduces the osteoclastogenic 
response 
127,128
. Cytokines such as IL-1 and IL-6 induce osteoclast formation via 
PGE2
126
 and conversely, PGE2 stimulates the release of these same cytokines. There 
appears to be a synergistic interaction between PGE2 and IL-1 or IL-6 culminating with 
RANKL production and OPG inhibition. Although in mice PGE2 seems to promote 
bone degradation, studies in human reveal conflicting data. In human peripheral blood 
mononuclear cells (PBMC), PGE2 inhibited RANKL/M-CSF-induced osteoclast 
formation, while in bone marrow cell cultures PGE2 had an opposing effect
126
. 
PGE2 is found in large amounts in RA synovial fluid 
129
 and coordinates several 
mechanisms involved in the pathogenesis of rheumatoid arthritis. The synovial tissue is 
highly proliferative and relies on new vessel generation for oxygen supply. As such, 
PGE2 stimulates the vascular endothelial growth factor (VEGF) production in 
fibroblasts
130
 thereby contributing to angiogenesis. The destruction process in 
rheumatoid arthritis involves degradation of cartilage and bone. Important in 
contributing to cartilage destruction, PGE2 mediates proteoglycan degradation in 
osteoarthritis cartilage extracts
131
 and inhibits de novo collagen synthesis
132
. As pointed 
out earlier, PGE2 contributes to skewing the immune response towards a Th17 
phenotype in the synovial microenvironment further enhancing release of inflammatory 
cytokines and promoting bone degradation. In vitro stimulated synoviocytes mount an 
impressive response in PGE2
133
, while synovial biopsies from RA patients are known to 
express enzymes of the PGE2 biosynthesis pathway
134
.  
EP4 receptor antagonist relieves joint pain and inflammation in animal model of 
arthritis 
135
. Moreover, EP4 is the receptor responsible for mediating PGE2 destructive 
potential in arthritis, since only the EP4 and not the other receptor knockout animals 
displayed reduced incidence of CIA, along with less cartilage and bone destruction 
compared to their wild-type littermates
136
. Also, macrophages isolated from mice 
lacking EP4 are less prone to produce TNF and IL-6
136
. 
Fatigue, a common complaint of RA patients, is caused by proinflammatory 
cytokines acting on the blood-brain barrier and inducing brain formation of PGE2, 
which signals further to the central parts of the brain
137
. 
Biosynthesis of PGE2 is catalyzed by various PGE2 synthesizing enzymes, either 
microsomal or cytosolic (MPGES1 and -2 or cPGES,). MPGES1 is the major enzyme 
of the PGE2 synthesis in inflammatory conditions and will be discussed in detail in the 
next chapter. MPGES-2 is constitutively expressed in many tissues, with high levels 
reaching in the brain, heart, muscle, liver and kidney
138
. Although cPGES is 
ubiquitously and constitutively expressed in most cells, pro-inflammatory stimuli in 
brain tissue were shown to increase its activity and expression
139
.   
Prostaglandins leave cells and enter extracellular compartment driven by pH and 
membrane potential or through active PG transporters, proteins with broad tissue 
distribution
140
. 
The local PGE2 concentration depends on the balance between synthesis and 
degradation. Inactivation of PGE2 is carried out by 15-prostaglandin dihydrogenase 
(15-PGDH). There are two types of 15-PGDH: type I (referred throughout this book to 
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as 15-PGDH) catabolizes specifically PG and other eicosanoids, while type II exhibits 
broader substrate specificity and is  believed to have minor function in the catabolism 
of PGs
141
. In the next paragraphs I will focus on the main enzymes involved in 
synthesis and degradation of PGE2, namely MPGES1, COX and 15-PGDH, with 
particular emphasis on inflammatory arthritis conditions. 
PGE2 biosynthesis - MPGES1 and COX enzymes 
Synthesis of PGE2 is dependent on the amount of AA available and on the presence of 
its synthesizing enzymes, MPGES1 and COX. Of the two COX isoforms, MPGES1 is 
coupled functionally mostly with COX-2, as they also co-localize 
137,142
 and can be co-
regulated in many cases. However, the promoter region of MPGES1 gene, unlike 
COX-2, displays few transcriptional elements typical to cytokine-induced genes
143
, 
indicating that MPGES1 and COX-2 have divergent mechanisms operating for 
regulation of their induction. 
MPGES1 is an inducible, 16.5 kDa enzyme belonging to the MAPEG (membrane 
associated proteins in eicosanoid and glutathione metabolism) family which includes 
six human proteins
144
. The highest homology to MPGES1 is found in microsomal 
glutathione S-transferase 1 (MGST1). All members of the MAPEG family are 16-18 
kDa integral membrane proteins, have a conserved six aminoacid sequence and share 
similar hydropathy profiles. In addition to the two previous mentioned human proteins, 
the MAPEG family comprises also the human 5-lipoxygenase activating protein 
(FLAP), leukotriene C4 synthase (LTC4 synthase), MGST2 and MGST3. Within the 
cells, MPGES1 resides in the nuclear and endoplasmic reticulum membranes and on 
sub-cellular fractionation it is found in the microsomal fraction
110
. 
COX enzymes are membrane bound proteins found as two isoenzymes; although 
their functional role is not absolute, COX-1 is a constitutive enzyme expressed virtually 
in all tissues of the body and its products serve homeostatic functions, such as 
gastroprotection and haemosthasis
108
. Its gene promoter does not possess any elements 
reminding of an inducible gene; however modulation of COX-1 expression has been 
reported
145
. COX-2 is induced by cytokines and mitogens which increase transcription 
but also stability of mRNA 
146
, resulting in increased protein expression. It largely 
accounts for the prostaglandins formed in inflammation and cancer, but it can also be 
constitutively expressed in brain and kidney 
147,148
. In contrast to its housekeeping 
functions, COX-1 deletion does not result in a severe phenotype in mice under 
physiological resting conditions, while COX-2 deficient mice display altered functions 
in several organs, including kidney, heart and reproductive organs
149
.  
Although constitutively expressed in a few human tissues, such as prostate, testis
150
, 
stomach, muscle tissue
151
, the main function of MPGES1 is to upregulate PGE2 
formation in pathologies associated with inflammatory response. LPS was the first to 
demonstrate co-induction of MPGES1 and COX-2 in rat peritoneal macrophages
152
. 
Other known MPGES1 inducers are IL-1β150, TNF, IL-6. Enzyme upregulation in 
response to inflammatory stimuli can be observed in fibroblasts, macrophages, 
osteoblasts, endothelial cells, smooth muscle cells, chondrocytes, and 
cardiomyocytes
153,154
. The  molecular mechanisms responsible for MPGES1 induction 
can be different depending on cell type and activation stimuli, but common final 
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pathways may lead to activation of transcription factors such as NF-κB and Egr-1 
(early growth response gene)
155
. Subsequently, a large number of genes involved in 
inflammatory responses are transcribed, among others MPGES1 and COX-2 
156,157
. 
Co-expression of MPGES1 and COX-2 in several tissues led to the assumption that 
these two enzymes may also be functionally coupled. This was demonstrated in rat 
peritoneal macrophages, synovial cells, gastric tissue and symptomatic atherosclerotic 
plaques
110
 where co-ordinate upregulation of COX-2 and MPGES1 was followed by a 
major PGE2 response. Also, co-localization in endothelial cells from the blood-brain 
barrier in response to peripheral inflammation, such as adjuvant induced arthritis, 
suggests a coupled system that elicits PGE2 brain formation with subsequent fever and 
pain perception. Parallel suppression of MPGES1 and COX-2 reflects their co-
induction, as dexamethasone abolishes enzyme formation and PGE2 production in 
A549 cells, synoviocytes, macrophages and osteoblasts 
110,133,158
. 
Several experimental models of acute and chronic inflammation in rats or knockout 
mice as well as human studies have demonstrated the role of MPGES1 and COX-2 in 
arthritis. In rat adjuvant induced arthritis 
159,160
 as well as carageenan-induced paw 
inflammation 
161
, induction of MPGES1 and COX-2 was found in the inflamed rat paw. 
Mice lacking MPGES1 develop a milder collagen induced or antibody induced arthritis 
compared to wildtype controls, have lower incidence and less evidence for bone 
destruction
162,163
. A similar arthritic phenotype is obtained in mice lacking cPLA2, 
COX-2 
164
 or EP4 receptors 
136
, suggesting a role for the cPLA2-COX-2-MPGES1-EP4 
axis in pathogenesis of at least rodent arthritis. As opposed to COX-2, mice lacking 
COX-1 were not protected from developing the disease and they had similar incidence 
and histopathology findings as wildtype COX-2 mice. Antigen-induced paw edema and 
pain is markedly reduced in MPGES1 knockout mice 
162
, with associated less cellular 
infiltration. MPGES1 derived PGE2 also plays a role in angiogenesis, since MPGES1-/- 
mice display less VEGF expression in the granulation tissue and reduced vessel 
formation.  
In humans, MPGES1 and COX-2 are present in the rheumatoid arthritis synovial 
lining cells, mostly fibroblasts and macrophages
134
, with higher expression levels in 
active versus inactive arthritis
154
. Several factors present in the rheumatic joint 
upregulate MPGES1 expression, usually in concert with COX-2, as is the case for the 
classical inflammatory mediators IL-1, TNF, IL-6165,166, but also for adiponectin167 
and epidermal growth factor
168
. In addition, PGE2 can autoregulate its own production 
by increasing MPGES1 gene expression, a mechanism possibly responsible for a 
vicious circle of inflammation
125
. Parallel downregulation of COX-2 and MPGES1 by 
glucocorticoids might involve suppression of NF-kB and Egr-1 transcription and was 
demonstrated in a number of in vitro systems 
133,158
. Both condrocytes and synovial 
fibroblasts in ostheoarthritis display MPGES1 and COX-2 expression that can be 
upregulated by inflammatory cytokines, similarly to RA
169
 .  
COX-2 and COX-1 are both expressed in synovial tissue of RA patients and in 
synovial cells
170,171
, while osteoarthritic tissue displays less COX-2 expression
172
. 
Increased expression in time was observed for COX-2 during development of arthritis 
in rats
170,173
, as well as the appearance of MPGES1 positive cells in CIA rat paws even 
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before clinical onset of the disease (Westman M. unpublished data), suggesting a role 
for this system in the early pre-clinical phase of arthritis in rats.  
In all, existing data points to inducible PGE2 as important contributor to rheumatoid 
arthritis pathogenesis, through expression of its synthesizing enzymes in the synovial 
tissue, high levels of PGE2 in the fluid and marked reduction in disease severity in 
rodent models lacking an active pathway. 
However, the role of PGE2 in promoting inflammation is not generally accepted and 
has been questioned in RA by the observation that NSAIDs can increase TNF 
production while addition of PGE2 can reverse this effect
174
. This, together with the fact 
that NSAIDs have not proven to retard disease progression, have led to the hypothesis 
that pathogenic mechanisms in rodents may not fully reflect the events in human RA.  
 
 
 
Fig.2 MPGES1 expression in rheumatic conditions associated with synovial 
inflammation. MPGES1 positive cells (brown) are seen in RA, PsA and OA synovial 
membranes and also in OA chondrocytes.  
PGE2 degradation - 15-PGDH 
15-PGDH is the key enzyme in the metabolism of prostaglandins, being responsible for 
reducing PGs to compounds with minimal biological activity. Apart from PGs, 
monocyte-derived 15-PGDH can also degrade lipoxin A4
175
 and a few other 
eicosanoids
176
. It is a 29kDa protein expressed in most tissues, with high levels in lungs 
where most PG degradation occurs. Interestingly, there are reports showing reciprocal 
regulation of COX-2 and 15-PGDH, for instance IL-1β and TNF upregulate COX-2 
while decreasing 15-PGDH expression. In addition, indomethacin, a NSAID blocking 
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COX-2 increases its expression, and IL-10 relieves the suppressing action of TNF and 
IL-1 on 15-PGDH. Furthermore, vitamin D treated neonatal monocytes increase 15-
PGDH transcription while decreasing COX-2, with a net decrease in PGE2 during 
osteoclastogenesis
177
. As part of the systemic inflammatory response, the 
transcriptional downregulation of 15-PGDH contributes to an increased PGE2 
level
178,179
.  
15-PGDH has received most attention in cancer-related studies, in which low levels 
of the enzyme were shown to correlate with cancer progression, in line with COX-2 
overexpression and high levels of PGE2 promoting carcinogenesis. Reduction in 15-
PGDH expression is a poor prognostic factor and is associated with an aggressive 
phenotype in several types of malignancies 
180,181
 . In inflammatory bowel disease- an 
autoimmune disorder- the inflamed mucosa displays lower levels of 15-PGDH than 
unaffected tissue, while in vitro TNF suppresses 15-PGDH transcription in 
colonocytes. Surprisingly few studies investigated 15-PGDH in arthritis, although the 
pathogenic role of PGE2 in this context has long been recognized. In mouse articular 
chondrocytes, IL-1 and adipocyte-derived factors were found to inversely regulate 
MPGES1 and 15-PGDH; the constitutively expressed 15-PGDH mRNA is decreased 
while MPGES1 is enhanced
182
.  
Lipoxygenase pathway 
There are several lipoxygenases catalyzing the formation of a large number of 
compounds with different biological activities. Pathways including 5-lipoxygenase and 
15-lipoxygenase have high relevance for inflammatory disorders, as they form potent 
pro-inflammatory mediators largely studied in conditions such as asthma, cardio-
vascular disorders and arthritis. These enzymes also synthesize anti-inflammatory 
compounds involved in limiting the inflammation extent and restoring tissue 
homeostasis. 
Stemming from the common precursor arachidonic acid, leukotrienes are generated 
after initial formation of an intermediate leukotriene (LT) A4 by 5-lipoxygenase. 
Subsequently, LTA4 can follow the pathway leading to cysteinyl leukotrienes or LTB4 
synthesis. LTA4 hydrolase gives rise to a potent proinflammatory eicosanoid termed 
LTB4, while LTC4 synthase forms LTC4 and in subsequent steps, LTD4 and LTE4, 
compounds generally referred to as cysteinyl leukotriens (CysLT), well known for their 
role in asthma pathogenesis.  
15-LO acting on AA gives rise to 15-hydroxitetraenoic acid (15-HETE) and when 
acting in concert with 5-LO through transcellular metabolism, can form anti-
inflammatory lipoxins. A new class of compounds termed eoxins is synthesized in 
eosinophils and mast cells through the 15-LO pathway and are believed to promote 
vascular permeability with edema formation
183
.   
5-lipoxygenase and LTB4 
5-LO, a key enzyme in LTB4 synthesis, is mostly expressed by cells of myeloid 
lineage, particularly neutrophils, monocytes/ macrophages, mast cells, basophils and B 
cells. It is a 78kDa soluble protein with variable cell localization requiring calcium for 
its activity. Whether located in cytosol or nucleus, 5-LO translocates to the nuclear 
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membrane upon cell stimulation, while 5-LO activating protein (FLAP) transfers AA to 
5-LO for efficient 5-LO activity. In monocytes, 5-LO expression is increased during 
migration and differentiation into macrophages. 
LTB4 is one of the most potent inflammatory mediators among eicosanoids, with a 
wide range of effects on leukocyte functions. LTB4 signals through two types of 
receptors. BLT2 has low affinity for LTB4 and is more widely expressed in human 
tissues; BLT1 is a high affinity receptor expressed predominantly in leukocytes, 
including neutrophils, monocyte/ macrophages, mast cells, T lymphocytes and mast 
cells 
184,185
.  
LTB4 has broad functions in regulation of the immune system including neutrophil 
chemotaxis, migration through endothelium and activation 
186,187
; activation of adhesion 
molecules expression 
188
, activation and induction of cytokine production in monocytes 
189
 as well as activation of B cells and T cells 
190,191
. Th1 and Th2 cells upregulate 
BLT1 expression on their surface while migrating out of the lymphoid organs and this 
receptor mediates the LTB4-induced Th cell adhesion to endothelial cells and migration 
to inflamed tissue 
192
. Also, activation of dendritic cells by LTB4 enhances their 
migration to the draining lymph nodes where they interact with antigen-specific cells. 
Recent reports have revealed also LTB4 to be a suppressor of T regulatory cells while 
promoting Th17 generation, with important implications in autoimmunity
193
. It is 
essential in host defense against bacteria 
194
 and is linked to the pathogenesis of many 
inflammatory disorders, such as asthma, atherosclerosis and rheumatoid arthritis.  
Earlier studies have documented increased levels of LTB4 in synovial fluid from RA 
compared to degenerative arthritis 
195
 and also higher concentration in seropositive RA 
compared to seronegative RA 
196
. Moreover, both receptors have been described in 
synovial tissue of RA patients, with higher BLT2 levels, especially in synovial lining 
cells 
197
. An essential contribution of LTB4 and BLT1 receptors to arthritis was 
demonstrated in several studies using animal models, either CIA or serum transfer 
model. In a study employing mice deficient in several of the LT cascade enzyme, it was 
shown that 5-LO and LTA4 hydrolase deficient mice are markedly resistant to 
development of disease, but not LTC4 synthase null mice, suggesting that LTB4 holds a 
pivotal role in pathogenesis. In addition, neutrophil-derived LTB4 is required for 
arthritis development of the disease, as transfer of these cells into 5-LO deficient mice 
restores the disease 
198
. BLT1 receptor is essential in mediating LTB4 effects in CIA 
model, since mice knocked out for this receptor are completely protected from 
developing arthritis 
199
. BLT1 -/- mice do not show any clinical or histopathological 
signs of arthritis, with complete absence of neutrophils and T cells from joints in 
immunized mice, suggesting an early role for LTB4 and BLT1 in disease development. 
Moreover, not only is LTB4 essential for leukocyte recruitment and activation in the 
joint, but also promotes their invasive and destructive behavior of fibroblast-like 
synoviocytes in the pannus
200
. As such, LTB4 may play a role in the early initiating 
pathogenic steps but also in the progression of arthritis.  
15-lipoxygenase - 15-HETE and lipoxins 
There are two 15-LO isoforms that differ in their enzymatic activity and tissue 
distribution. 15-LO-1 is constitutively expressed mostly by reticulocytes, eosinophils, 
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dendritic cells and airway epithelial cells 
201,202
, whereas 15-LO-2 is present mostly in 
hair roots, prostate and cornea. Given the expression profile and the distinct biological 
functions of the two isoforms, 15-LO-1was extensively investigated in conditions 
where immune responses play central roles. As 15-LO-1 participates in forming both 
anti-inflammatory-mediating compounds, such as lipoxins but also directly derived 
eicosanoids with debated biological properties, such as 15-HETE, it is not 
straightforward to predict how this pathway contributes to inflammatory disorders. 
Expressed in a few cell types in resting conditions, 15-LO-1 can also be induced by 
cytokines in many different cells. Importantly, while peripheral blood monocytes do 
not readily express 15-LO, they are able to induce its expression through IL-4 and IL-
13 stimulation while IFNγ suppresses the induced expression 203. In vitro differentiated 
dendritic cells express 15-LO and IL-13 stimulation of rabbit endothelial cells results in 
upregulated protein expression and generation of vasodilator mediators
204
.   
The main compound formed by 15-LO is 15-hydroxyeicosatetraenoic acid (15-
HETE) after initial synthesis of an unstable intermediate, the 15-
hydroperoxyeicosatetraenoic acid. 15-HETE is a mediator with modulating effects on 
the immune system. There are contradictory data regarding its pro- or anti-
inflammatory signaling pathways in diseases. This is in part due to a complex 
relationship between 15-LO products and inflammation-related signaling pathway, such 
as PPARγ, with inhibitory or activating signals depending on cell type, stimuli, disease 
model and other poorly understood factors.  
High 15-LO expression and 15-HETE formation in airways of asthmatic individuals 
as well as stimulation of neutrophil chemotaxis in dog airways 
205
 suggested a role in 
the bronchial inflammation. In line with pro-inflammatory effects of 15-HETE, a recent 
study revealed its ability to stimulate NF-κB transcription factor and related cytokines 
in human monocytes 
206
. 
Lipoxins can be formed, among different pathways, by transcellular biosynthesis 
through coordinate actions of 5-LO and 15-LO in different cell types. Lipoxins, in 
particular lipoxin A4, reduce neutrophil chemotaxis and degranulation
207
, promote 
leukocyte apoptosis and their phagocytosis, thereby evoking signals that stop the 
inflammatory response, and contribute to resolution and restoration of tissue integrity. 
Lipoxin A4 receptor was demonstrated to be expressed in RA biopsies, with LXA4 
levels increased in RA compared to OA
208
. 
Animal models of atherosclerosis, an inflammation – related disorder, delivered 
conflicting results regarding the role of 15-LO. Disruption or blocking this enzyme 
resulted in diminished atherosclerosis
209,210
, with less macrophage infiltration whereas 
other studies showed that overexpression of 15-LO reduced atherosclerosis 
development with decreased size and number of vascular lesions 
211,212
.  
The relevance of 15-LO as negative regulator of inflammation has been suggested in 
a rabbit periodontitis model in which overexpression of 15-LO reduced inflammation 
and tissue damage
213
. In addition, mice lacking 12/15-LO (the murine homologue of 
15-LO) suffered prolonged eye wound healing 
214
. Also, macrophages from 12/15-LO 
knockout mice mounted an increased inflammatory response to activating stimuli and 
displayed abnormalities in cytokine response to bacterial products
215
.  
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In an earlier study of carrageenan-induced arthritis in dogs, intra-articular 15-HETE 
injection inhibited the LTB4 formation and recruitment of neutrophils, along with 
decreased severity of arthritis 
216
. In line with an anti-inflammatory role for 15-LO, 
12/15 LO deficient mice displayed exacerbation of collagen-induced arthritis with 
marked destruction of the joint and increased osteoclasts number 
217
. Further relevant to 
human arthritis, 15-LO-1 has been shown to be present at mRNA level in RA synovial 
biopsies and can be upregulated in vitro by IL-4 in synovial fibroblasts
218
. 
In short, 15-LO-1 pathway and its products can display diverse actions in 
inflammatory conditions with many studies pointing to an anti-inflammatory effect, at 
least in animal models of chronic inflammation.   
There is a lack of studies investigating how anti-rheumatic treatment influences 
locally the eicosanoid pathways with relevance to RA pathogenesis, such as PGE2 and 
LTB4 biosynthesis. Studies on the effects of anti-rheumatic treatment on 5-LO pathway 
have provided conflicting results. There are reports documenting inhibition of LTB4 
formation or 5-LO expression by glucocorticoids 
219
, as well as opposing results 
220,221
, 
with differences residing in cell type studied- peripheral blood cells, neutrophils, 
monocytes-, incubation time as well as concentrations used.  
In addition to its effects on cytokine production and cell proliferation, methotrexate 
can also influence lipid derived mediators, such as cyclooxygenase derived products. 
However, the effects on these pathways are not entirely delineated; reports indicate 
decreased joint PGE2 formation in rabbits receiving methotrexate, but also no effect or 
decrease in IL-1 induced PGE2 release in cultured RA synovial fibroblasts 
76,222
. Still, 
no studies were undertaken to address the local effect in the synovial compartment of 
methotrexate therapy on the enzymes involved in PGE2 synthesis and metabolism. 
Hence, we felt the need to explore this pathway and the influence of common and 
newer anti-rheumatic drugs on enzyme expression. 
Since therapy for RA may be extremely efficient for some patients, even though not 
curative, but not for others, it is important to investigate how these drugs target 
pathways known to have deleterious effects in RA, such as the eicosanoids. On one 
hand, are there active pathways in these patients that may explain their lack of 
response? On the other hand, in patients responding to treatment, can these 
inflammatory mediators be responsible for incomplete response or relapse, in other 
words, is the eicosanoid cascade targeted or not by current medication?  
Through the results presented in this thesis I will try to provide some answers to 
these questions and a basis for possible new targets or combination therapies in RA. 
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AIMS OF THE THESIS 
Given the importance of lipid mediators in inflammatory reactions and their presence in 
the synovial fluid of rheumatoid patients, we aimed to: 
- describe the distribution of enzymes responsible for their metabolism in synovial 
tissue 
- investigate how current anti-rheumatic agents target prostaglandin and leukotriene 
pathways, more specifically TNF antagonists, intra-articular glucocorticoids, rituximab 
and methotrexate 
- determine the essential structural elements in MPGES1 activity as a basis for future 
inhibitor studies 
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RESULTS AND DISCUSSION 
Enzymes involved in the formation of inflammatory lipid mediators are present in 
RA synovial tissue and are targeted by intra-articular GC therapy (Paper I, II, III 
and IV) 
Synovial tissue from RA patients is rich in MPGES1
134
 enzyme while in vitro 
synoviocytes are known to upregulate expression of enzymes comprising the PGE2 
biosynthetic pathway when challenged with pro-inflammatory stimuli
133
. In our first 
study (Paper I), we extended our analysis in synovial biopsies to examine in detail the 
distribution of COX enzymes in relation to MPGES1 expression. By using double 
immunohistochemistry, we demonstrated that MPGES1 and COX-2 display similar 
distribution and are in most cases co-localized in intimal lining layer, unlike COX-1 
positive cells that mostly lack MPGES1 expression. COX-2 expressing cells were seen 
among the synovial fibroblast and macrophage-like cells, but also endothelial cells in 
almost all patients, while only a small proportion of biopsies displayed MPGES1 
positive cells in vessels. Extensive staining for COX-1 was observed both in the intimal 
lining and sublining layers and, similarly to COX-2 and MPGES1, was almost absent in 
the lymphoid infiltrate areas. As demonstrated in Paper II, MPGES1 is not expressed in 
B cell rich areas where most CD20+ cells and plasma cells reside, like the follicular 
aggregates, but in the regions surrounding these structures, likely comprising 
macrophages and fibroblasts. 
The prostaglandin metabolizing enzyme, 15-PGDH was present in all RA synovial 
tissue biopsies evaluated (Paper III), while the extent of expression varied between 
samples most likely due to the degree of inflammation locally present. Not only was 
15-PGDH detected in RA biopsies, but also in synovial tissue from OA and psoriatic 
arthritis patiens, in accordance with these conditions displaying variable levels of 
synovial inflammation during the disease course. Most of the cells positively stained 
for 15-PGDH were intimal and sublining macrophages and fibroblasts, as well as 
endothelial cells.  The fact that 15-PGDH is present in the rheumatoid milieu and 
shows a similar cellular distribution to MPGES1 provides an evidence the PGE2 level 
can be adjusted locally by its synthesizing and degrading enzymes. Still, despite 
expression of 15-PGDH in RA tissue, PGE2 is found in high concentration in the 
synovial fluid
129
, possibly reflecting an intense biosynthetic activity. Indeed, potent and 
numerous MPGES1 stimulatory mediators including IL-1, TNF, IL-6 are all capable of 
sustaining constant PGE2 formation. 
Leukotriene synthesis is clearly ongoing in the rheumatoid joint, since the synovial 
fluid is rich in LTB4 and FLS
200
, monocytes
223
, neutrophils
224
, mast cells
225
 and 
osteoclasts
226
 are capable of producing LTB4 when appropriately stimulated. Animal 
studies have documented the importance of 5-LO pathway in RA pathogenesis and 
there are clinical trials evaluating the efficacy of blocking this pathway
227
. We 
underwent a detailed analysis of 5-LO and 15-LO expression in the synovium of RA 
patients and employed immunofluorescence technique to phenotype the cells 
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responsible for enzyme synthesis (Paper IV). In the rheumatoid synovium, 5-LO is 
present in the synovial lining and in scattered cells in the sublining, with a staining 
pattern suggesting nuclear localization. Most of the 5-LO positive cells are resident 
(CD163) and migrated (CD68) macrophages; even though in low number, mast cells 
and neutrophils can express 5-LO while T cells and, surprisingly B cells, do not. 
Several studies have documented LTB4 formation by B cells and it is well accepted that 
5-LO is expressed in these cells. Recently, expression of 5-LO was evaluated in B cell 
subsets and shown to be high in immature mantle zone IgD+ B cells, whereas plasma 
cells and germinal center B cells almost lack this enzyme
228
. On the other hand the 
majority of B cells in the synovium are memory CD27+ cells and very few naïve IgD+ 
cells
22
. Taken together, the lack of 5-LO expression in synovial B cells is a result of the 
specific B cell subsets present in the synovial tissue. 
15-LO enzyme was present both in the lining synovial cells and in the sublining 
region, mostly expressed by cells of the monocyte lineage and fibroblasts. In addition, 
most vessels in the tissue displayed 15-LO expression in CD31+ endothelial cells. As 
for 5-LO, no expression was revealed in T and B lymphocytes comprising 
inflammatory infiltrates. As opposed to RA, samples obtained from patients undergoing 
joint replacement surgery for osteoarthritis showed less pronounced expression of 
lipoxygenases. Indeed, chondrocytes and cartilage areas do not display enzyme 
expression (data not shown), whereas the few synovial membrane areas showed 
discrete 5-LO staining in macrophage-like cells; as a common feature to RA, 15-LO 
expression was detected in vessels and synovial lining cells.  
Glucocorticoids are highly efficient anti-inflammatory drugs and have a special 
place as adjuvant medication in RA but also in other inflammatory arthropathies owing 
to quick relief of inflammation and related symptoms, but also to their proven bone-
protective effect in low-dose oral administration and as intra-articular injection. We 
have studied the influence of intra-articular therapy on the eicosanoid pathway in 
synovial tissue (Paper I, III, IV) and shown that enzymes involved in formation of 
potent inflammatory mediators are targeted by such treatment. In particular, MPGES1, 
COX-2, and surprisingly COX-1, all responsible for the PGE2 metabolism, as well as 5-
LO, involved in formation of leukotrienes showed decreased synovial expression 
following local therapy with glucocorticoids. Despite most often regarded as a 
constitutive protein with ubiquitous expression, COX-1 can also be upregulated in 
response to IL-1 in synovial fibroblasts
229
. In this system, dexamethasone was shown to 
downregulate both COX-1 and COX-2 expression, which is in line with our results. 
Possibly, COX-1 induction is cell-specific and stimulus-dependent and in RA it is 
sensitive to mediators present in the inflamed tissue.  
As expected for a constitutive enzyme, cytosolic PGES was not influenced by intra-
articular GC. Although not achieving statistical significance, 15-PGDH showed a trend 
towards reduced expression (p=0.07), suggesting its dual role as regulator of catabolism 
for both pro-inflammatory and anti-inflammatory compounds. When it comes to 15-LO 
expression, albeit not significantly influenced at the group level, it was reduced in a 
high proportion of patients, while only 2 out of 11 showed increased staining. While 
15-HETE, the main product of 15-LO-1 is regarded as a pro-inflammatory mediator, 
many studies claim the beneficial role for 15-LO-1 pathway in inflammation through 
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participation in lipoxins synthesis. As such, transgenic TNF mice lacking 15-LO 
showed a much more severe arthritic phenotype than those having an active 15-LO 
pathway with increased systemic expression of IL-6 and IL-1
217
. Moreover, the levels 
of lipoxin A4 were decreased in knockout animals and correlated with high expression 
of pro-inflammatory cytokines and tissue damage, suggesting an important contribution 
of lipoxins to the modulation of inflammatory response. In this study, 15-HETE 
displayed anti-inflammatory properties by reducing TNF-induced IL-6 in macrophages. 
We have shown that in the synovial fluid, 15-LO can catalyze the formation of 15-
HETE upon exogenously added arachidonic acid, albeit the amounts detected were 
rather small. Moreover, we could not detect any 15-HETE in freshly isolated synovial 
fluid, since the values were under the detection limit for the enzyme immunoassay 
method we used. This can also be due to the fact that readily formed 15-HETE can 
undergo transformation by 5-LO into LXA4, a common pathway for lipoxin 
biosynthesis
230
, since both these enzymes are present in the tissue and synovial cells. In 
this sense, increased expression of 15-LO after GC treatment as seen in 2 of our study 
patients may be related to better anti-inflammatory effects. 
Earlier studies have documented the inhibitory effect of GC on leukotriene pathway, 
by reducing both expression of 5-LO and formation of LTB4
196,219,231
, which is in line 
with our results. Knowing the role of LTB4 in inducing bone loss in inflammatory 
conditions
226
, reduced LTB4 levels as achieved by GC may contribute to their bone-
protective effect. In addition, as LTB4 is a potent chemotactic agent, another 
consequence of lowering its concentration is diminished cellularity in the synovial 
tissue. As such, reduced 5-LO expression with consequent decrease in leukotriene 
production in the rheumatoid milieu provides additional mechanisms by which intra-
articular GC therapy exerts its beneficial effects. 
Despite elevated LTB4 levels in several inflammatory conditions and strong 
evidence from animal and in vitro data for a pathogenic role, clinical trials evaluating 
inhibitors of this pathway have been disappointing and failed to show efficacy so far
227
. 
Possibly, the assays evaluating these compounds in peripheral blood cells were not 
suitable to reflect the effects at the site of inflammation
232
. Another aspect is the 
heterogeneity of inflammatory diseases, with possible variation in the levels of LTB4 
among subgroups of patients, so that the patient population needs to be carefully 
selected. Lastly, RA is a disorder with complex network of mediators, where a 
combination therapy may prove more efficient than monotherapy. 
Lipid mediators of the innate immune response are refractory to TNF blocking, B 
cell depletion or methotrexate treatment 
The development of TNF blockers and their success in RA treatment has opened new 
possibilities for the care of rheumatic patients and provided a proof of concept that 
targeting distinct pathways may result in profound therapeutic benefit. It also set the 
ground for investigating and understanding which processes in the joint are essential for 
efficient response to treatment. The efficiency of B cell depleting therapy in RA 
underscores the role of B cells in coordinating immune responses in the synovium and 
suggests that disruption of the autoreactive circuits may be central in re-establishing 
immune homeostasis. Methotrexate has long held a central role in RA therapy and  its 
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ease of administration, acceptable safety profile and good efficiency in terms of 
protection from joint destruction
233
 have made it the dominant DMARD and the first 
choice in treatment during the past couple of decades
18
.We chose therefore to 
investigate how these efficient RA therapies influence the prostaglandin E2 biosynthetic 
pathway, known to regulate important processes in the disease pathogenesis. 
We investigated the expression of MPGES1and COX-2, the inducible enzymes of 
the PGE2 axis in synovial biopsies obtained from two groups of patients treated with 
TNF blockers (Paper I); the first group included 8 patients receiving etanercept and the 
second group 10 patients with infliximab treatment. No significant influence in the 
expression of either enzyme could be detected for any of the two TNF blockers 
evaluated. TNF is an important contributor to MPGES1 and COX-2 upregulation in 
different cell systems
158,165,234
; still other more potent stimulators also promote PGE2 
induction along with TNF. Indeed, we and other investigators have demonstrated that 
IL-1β induces a stronger upregulation of PGE2 (Fig. 3) and MPGES1 mRNA
133
 than 
TNF in cultured synoviocytes; moreover, IL-1 expression may remain unchanged 
following treatment with TNF blockers
235
. Also, HMGB1 (high mobility group B1) is 
another candidate pro-inflammatory molecule expressed in RA tissue
236
, able to induce 
PGE2
237
 and not targeted by anti TNF therapy
238
. As a result, induction of PGE2 
producing enzymes continues despite important reduction in the synovial inflammatory 
load. On the other hand, therapy with TNF antagonists was shown to diminish 
monocyte/ macrophage population
94
, where much of the MPGES1 and COX-2 reside, 
besides fibroblasts, and to reverse NF-κB activation239. This could hypothetically result 
in lower number of cells expressing these enzymes and reduced levels of pro-
inflammatory mediators that could induce them. However, our data suggest that the 
level of enzyme expression is not a simple mathematical compilation of numbers of 
cells and mediators, but the result of a complex network of cell interactions and 
regulatory feedbacks.  
Fig. 3 Formation of PGE2 in RA cultured fibroblast-like synoviocytes treated with IL-
1β or TNF for 24h. 
In order to avoid confounding effects in the synovial analysis, patients treated with 
rituximab (Paper II) did not receive prednisolon pre-treatment along with the 
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infusions, as is the standard administration procedure to minimize risks for allergic 
reactions. Biopsies were prelevated from 24 patients before first infusion as well as at 
two consecutive timepoints, 4 and 16 weeks later. Patients enrolled in this study had 
active RA, defined as ≥ 4 swollen and tender joints in the 28 joints assessed and at least 
one of the following criteria: erythrocyte sedimentation rate ≥ 28mm/h, serum C-
reactive protein ≥ 15mg/ liter, or morning stiffness ≥ 45min. In addition, all patients 
were positive for either rheumatoid factor or ACPA and had active arthritis in at least 
one joint accessible for arthroscopy. Investigation of MPGES1 and COX enzymes 
revealed that their expression remains essentially unaffected by this therapy and no 
association pattern can be seen with clinical course or depletion of CD22 positive B 
cells in the synovial tissue (data not shown). We next analyzed cytokines known to 
induce these enzymes in the rheumatoid compartment and demonstrated that indeed 
rituximab, despite depleting macrophage and T cell populations
100
 in the tissue, has 
limited influence on IL-1β and IL-6 expression.  
An important implication of an earlier finding that antibody production depends on 
COX-2 expression in peripheral blood B cells
240
 is that autoantibody formation as seen 
in rheumatoid arthritis may be altered by interventions targeting this pathway. 
However, we were not able to demonstrate any MPGES1 expression in either CD20+ B 
cells or plasma cells in the synovium so it is unlikely that these cells form PGE2 even 
though some might express COX-2. We know that B cells in the peripheral blood may 
differ substantially in behavior from synovial fluid B cells (see later in vitro results), 
and possibly also from the repertoire present in the rheumatoid synovium
22
, although 
detailed phenotypic comparative analysis is lacking. It seems that B cells in synovial 
tissue are not a source of PGE2, but may however respond to it through EP receptors 
present on their surface
241
. In addition, persistent PGE2 during rituximab treatment may 
herald relapse by supporting viability of replicating B cells 
242
 that were not completely 
removed from the tissue, thus promoting B cell expansion in the synovium. PGE2 is a 
complex stimulus, given the B cell expression of four EP receptors, so, while trying to 
understand the effects of PGE2 on synovial B cells, it is important to keep in mind that: 
1) the sensitivity to PGE2 depends on B cell developmental state
243
; and 2) each EP 
receptor subtype mediates unique functional responses. It was recently shown that 
PGE2 promotes survival pathways in dividing B lymphoblasts through upregulation of 
EP2 receptor
242
, while in another study PGE2 suppressed B cell proliferation via EP4 
receptors
121
. As such, the net result of remnant PGE2 in the synovial tissue after 
rituximab therapy remains to be further evaluated; however, persistence of other 
cytokines as IL-1β and IL-6 suggests an active ongoing inflammation. 
 In the methotrexate study group (Paper III), we extended our analysis to include 
enzymes involved both in synthesis and degradation of PGE2. As such, we studied the 
expression of MPGES1, COX-1, COX-2 and 15-PGDH in a group of 13 early RA 
patients naïve for methotrexate treatment and newly diagnosed. After a median of 8 
weeks following therapy start, synovial biopsies showed no change in enzyme 
expression either in the whole group or when analyzing subsets of patients stratified on 
response to treatment or autoantibody positivity. However, the small size of our study 
group, with few patients in each analyzed subgroup precludes a definite conclusion in 
the general RA population, but rather gives a hint that at least in some patients this 
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pathway remains functional. Validation in a larger cohort or evaluation of pre-defined 
subsets of patients may reveal effects specific for distinct pathogenic groups. 
Methotrexate was shown to inhibit the expression of IL-1β in RA synovial tissue244 
and that of TNF in responder patients
245
  together with reduction in macrophages, T 
cells and plasma cells four months after therapy start. The decrease in adhesion 
molecules
244
 is thought to account for the reduced cellularity. Alternatively, the induced 
adenosine may inhibit leukocyte accumulation
78
. We demonstrated in this study that in 
early RA PGE2 pathway remains unaffected after the first 8 weeks of treatment. Since 
usually a trial of three months is allowed for evaluation of efficacy and additional 
improvement in disease activity can be achieved after this period
246
, later effects cannot 
be excluded. In short, we can conclude that targeting PGE2 is not one of the 
mechanisms responsible for early methotrexate efficiency. Despite significant reduction 
in RANKL expression in these patients
247
, some show ongoing bone destruction to 
which persistent PGE2 may contribute. 
Distinct effects of in vitro anti-rheumatic treatment on RA synovial cells (Paper I, 
II and III) 
Synovial fluid mononuclear cells (SFMC) were evaluated in vitro for the expression 
of PGE2 pathway enzymes in resting and stimulated conditions (Paper I). LPS is a 
classical and potent inducer of these enzymes, useful for studying effects of various 
treatments in activated monocytes that are sensitive to its stimulation. In addition, it 
mimics TLR ligands present in the rheumatoid joint. Both dexamethasone and the TNF 
antagonists tested – infliximab and etanercept- decreased the expression of MPGES1 
and COX-2 in CD14+ monocytes, while not influencing COX-1 expression. 
Accordingly, PGE2 accumulated in the culture supernatants as well as the amount 
formed after incubation of cultured cells with exogenous arachidonic acid mimicked  
the dynamics of enzyme expression – strong induction by LPS followed by 
downregulation by dexamethasone and anti-TNF agents. Glucocorticoids are strong 
inhibitors of the inducible enzymes MPGES1 and COX-2, without affecting 
constitutive COX-1, as demonstrated by studies in numerous in vitro systems. 
Infliximab and etanercept act by blocking TNF actions and may well result in 
interference with LPS-induced PGE2 system, since LPS stimulates the release of both 
TNF and IL-1β, either of which can induce MPGES1 and COX-2. Pro-inflammatory 
cytokines can exert distinct and specific effects on different cell types, depending also 
on the density and type of surface receptors. It was previously reported that anti-TNF 
treatment of mouse macrophages attenuates COX-2 expression in response to NF-κB 
activation
248
, while in other investigators reported that anti-TNF antibodies failed to 
block LPS-induced COX-2
249
. Our results suggest that in LPS-stimulated SFMC, the 
COX-2-MPGES1- PGE2 axis is TNF dependent. 
Staphylococcus aureus Cowan strain I (SAC) and pokeweed mitogen (PWM) are 
polyclonal B cell activators that induce B cell proliferation and activation; while SAC 
stimulates B cells independently of T cells, PWM is T cell-dependent. We used this 
powerful combination of stimuli to mimic the complex network of activating mediators 
in the rheumatic milieu and to assess the ability of B cells to express the enzymes of 
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interest while fully activated (Paper II). As demonstrated by flow cytometry analysis 
of CD19+ gated cells, resting B cells did not display MPGES1 or COX-2 enzymes 
either in periphery or in the synovial fluid, but once activated, synovial fluid B cells 
upregulated the expression of both enzymes to a higher level than peripheral blood B 
cells. This is in accordance with previous studies
122,240
 documenting COX-2 and PGE2 
induction in stimulated peripheral B cells. The difference in the level of expression 
attained by B cells originating from synovial fluid versus B cells from peripheral blood 
may be explained by specific subsets or activation states in the two compartments. A 
recent investigation reported MPGES1 expression in replicating cells
242
, as is the case 
in our experimental setting where the stimuli we used determine B cell proliferation. 
However, in the RA tissue there is little B cell proliferation
22
 and also rather few naïve 
B cells; there is also evidence that distinct B cell subsets may be activated by different 
factors
250
; therefore, the lack of MPGES1 expression in tissue B cells as detected by 
immunohistochemistry possibly reflects the difference in B cell subsets between tissue 
and fluid / blood but also the fact that our in vitro system may not faithfully reproduce 
the rheumatic environment.  
Fibroblasts-like synoviocytes were cultured in vitro and stimulated with IL-1β or 
TNF for 24h and 48h in order to test the best conditions for MPGES1 and COX-2 
induction (Paper III). In subsequent experiments IL-1β stimulation was applied for 
48h as this provided the strongest PGE2 formation. In vitro treatment with methotrexate 
was added as 10μM and 250μM, as the usual concentration attained in blood upon low-
dose weekly therapy is in the 100 μM range251. Both on a protein level, as assessed by 
MPGES1 and COX-2 western blotting, and on a functional level, reflected by 
formation of PGE2 and other eicosanoids of the cyclooxygenase pathway, methotrexate 
exerted no detectable effects. We observed stable protein levels and non-significant 
changes in prostaglandin formation in treated cells compared to controls. 
There are inconclusive studies regarding methotrexate effects on cytokine and lipid 
derivatives production in vitro. In synovial fibroblasts, methotrexate had no effect on 
IL-1 stimulated cytokine and PGE2 production
222,252
, while other study claimed reduced 
PGE2 level
253
 although in this latter investigation IL-1 was only added towards the end 
of the incubation period. It is also suggested that methotrexate inhibits TNF-induced 
NF-κB activation254. However, IL-1 and TNF, despite having sometimes redundant 
functions, differ in signaling pathways
255
. Taken together, the IL-1β- induced PGE2 
pathway in fibroblasts is resistant to methotrexate treatment, a feature in accordance 
with results obtained in ex vivo analysis of the same enzymes. 
MPGES1 and related enzymes persist in synovial tissue, particularly in fibroblasts 
despite anti-rheumatic treatment (see Paper II). These cells are capable to invade 
cartilage and start degradation processes in the absence of other effector molecules and 
also migrate from inflamed to non-affected joints
256
. It is well-known that PGE2 holds a 
central role in the aggressive nature of cancer cells
257
. Since RA pannus is sometimes 
regarded as a locally invasive tumor
6
, it is tempting to speculate that PGE2 could 
promote a similar character in synovial fibroblast-like cells and account for their 
invasive nature.  This remains however a hypothesis that needs to be tested. 
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Fig. 4 Cellular expression of PGE2 pathway enzymes in RA synovial tissue and the 
contribution of cells involved in this pathway to disease pathogenesis. PGE2, mainly 
produced in synovial macrophages and fibroblasts by inflammation-induced COX-2 
and MPGES1, promotes formation of new vessels (through increased VEGF 
expression), bone destruction (through reduced OPG and enhanced RANKL expression 
in fibroblasts and osteoblasts) and perpetuation of autoimmune reactions (through B 
cell survival and proliferation and Th17 expansion). At the same time, PGE2 may also 
dampen inflammation by reducing TNF and increasing IL-10 in macrophages. 
Macrophages and fibroblasts, together with endothelial cells, are also the cells capable 
of PGE2 removal by inactivation.  
Structural determination of human MPGES1 (Paper V) 
Large well-ordered two-dimensional crystals of purified human MPGES1 together 
with glutathione were grown in the presence of phospholipids. We determined the 
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structure by cryo electron microscopy to a resolution of 3.5 Å and showed that the 
enzyme displays four transmembrane α-helices and forms a trimer in the membrane, 
similar to other MAPEG proteins
258
. The active site where the substrate PGH2 gains 
access is found at the interfaces between two monomers and is stabilized by glutathione 
through specific aminoacid interactions. Comparison with LTC4 synthase
259,260
 suggests 
that there is a conformational change with an open MPGES1 structure allowing for 
substrate access. In addition, key aminoacids specific for the human enzyme, not 
present in rat or mouse proteins, participate in the interactions at the active site and may 
explain the lack of effect on rodent enzyme of inhibitors developed towards human 
MPGES1
261
. 
The data presented here, showing limited effects on PGE2 axis of traditional and 
newer therapies that are highly efficient in a large proportion of patients, suggests that 
pathways with inflammatory and destructive potential remain unaffected and may 
contribute to subclinical inflammation even in non-symptomatic joints
262,263
. It is 
already well-established that patients in remission present asymptomatic inflammation 
revealed by imaging techniques
264
 which is responsible for progressive joint 
destruction. When therapy is withdrawn, such apparent silent pathways may turn on 
interactive immune cell communications via EP receptors present on most of these cells 
and induce inflammatory reactions all over again.  
CONCLUDING REMARKS AND FUTURE DIRECTIONS 
During the past years, there has been an explosion of new drugs targeting specific 
pathways and events in the pathogenesis of RA, many of them with great impact on the 
disease course and quality of life for the rheumatic patient. Still, despite this 
tremendous improvement in therapy efficiency, there are still a high proportion of 
patients not adequately responding to treatment and, above all, drug-free remission has 
not been achieved, implying that the dysregulated inflammatory reaction is sustained by 
ongoing mechanisms. 
The results presented in this thesis suggest that therapy with methotrexate, TNF 
blockers or rituximab may leave an important inflammatory pathway, the COX-2 –
MPGES1 –PGE2 active in the rheumatoid synovial tissue. We have demonstrated that 
in newly diagnosed RA, starting of therapy with methotrexate does not abrogate PGE2 
biosynthetic pathway in synovial tissue after 8 weeks, a result supported also by in vitro 
data. In patients treated with infliximab or etanercept, 8-10 weeks following treatment 
we cannot confirm any effect on the PGE2 pathway. Despite in vitro data showing 
significant downregulation of this pathway, the results obtained in biopsies ex vivo 
support the idea that in order to assess the actual effect of a drug, it is important to 
evaluate the events at the site of inflammation. Similarly, in the cohort of patients 
starting rituximab treatment, biopsies obtained at 4 weeks and 16 weeks fail to provide 
evidence for any effect on the PGE2 pathway; in addition, inflammatory mediators 
known to induce the PGE2 biosynthetic enzymes were also not affected by this 
treatment. Hence, a therapeutic approach combining MPGES1 inhibitors with anti-
rheumatic drugs may provide benefit in controlling synovial inflammation. And lastly, 
efficient anti-inflammatory glucocorticoids deplete enzymes responsible for both PGE2 
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and leukotriene formation in RA synovial tissue, suggesting an additional mechanism 
that may explain its potent effects. 
It is noteworthy to mention in this context the widespread use of NSAIDs, well 
appreciated for relieving inflammation, pain and fever. Knowing the complexity of the 
eicosanoid pathway and the inter-relation between branches one can argue that 
blocking the whole COX pathway is a rather broad action. In this sense, reduced 
prostacyclin levels account for the cardiovascular side effects of these drugs, while 
reducing prostaglandin D2 and subsequently its degradation product, 15-deoxy-delta-
12-14-prostaglandin J2, may impair resolution of inflammatory processes. This suggests 
that drugs targeting MPGES1, the inducible enzyme in inflammatory conditions, may 
offer additional benefits not only by taking away inducible PGE2, but also by 
preserving or diverting the eicosanoid metabolism towards other bioactive lipids with 
pro-resolving properties.  
As it is usually the case, immunomodulating molecules cannot simply be judged as 
black or white, and it would be wrong to say that PGE2 is entirely “evil”, even in an 
inflammatory context. It is an important contributor to inflammation, to homing of cells 
at the site of inflammation while at the same time preparing the ground for resolution, 
by inducing lipoxin formation
265
. Moreover, COX inhibitors were shown to actually 
prolong inflammation when administered in the restoration phase 
266,267
. In fact, only 
recently a very intriguing study revealed that COX-2 is involved in both the 
inflammatory and resolution phases in collagen induced arthritis
266
. By depleting COX-
2-derived PGE2 in the resolution phase using COX-2 inhibitors, lipoxin A4 formation 
was blunted and tissue restoration was impaired.  Interestingly, MPGES1 was not 
expressed during resolution in this model, so the PGE2 necessary to restore tissue 
integrity is not dependent on MPGES1. Therefore, an attractive idea is that more 
targeted therapy as provided by inhibiting MPGES1 instead of COX could block 
inflammatory pathways while at the same time re-establishing tissue homeostasis. 
 PGE2 may also have protective effects in wound
268
 and fracture
269
 healing and 
important functions in cardiac remodeling following infarction, as demonstrated in 
mice lacking MPGES1
270
. It will therefore be an important issue and a challenge to 
keep the balance between deleterious and protective PGE2 effects while inhibiting 
MPGES1. 
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